drugset / Trial / NCT03283319
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
Phase 2
Completed
366 enrolled
Biomedical Advanced Research and Development Authority
Rho, Inc. · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated by 28 days. Three different antigen dose levels of Panblok H7 will be tested.
Timeline
- Start
- 2017-09-20
- Primary completion
- 2017-12-15
- Completion
- 2018-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AS03 | Other / unclassified | 0.5 ml | Intramuscular |
| Subject | MF59 | Other / unclassified | 0.5 ml | Intramuscular |
| Subject | Panblok H7 | Vaccine | 3.75 ug | Intramuscular |
| Subject | Panblok H7 | Vaccine | 7.5 ug | Intramuscular |
| Subject | Panblok H7 | Vaccine | 15 ug | Intramuscular |